Thorac Cardiovasc Surg
DOI: 10.1055/a-2768-2882
Short Communication

Postoperative Recurrence of ROS1-Rearranged Lung Adenocarcinoma: A Case Series

Autor*innen

  • Ryo Miyata

    1   Department of Thoracic and Cardiovascular Surgery, Nara Medical University, Nara, Japan
  • Ryota Sumitomo

    2   Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan
  • Ryo Nakanobo

    3   Department of Thoracic Surgery, Kurashiki Central Hospital, Okayama, Japan
  • Masatsugu Hamaji

    1   Department of Thoracic and Cardiovascular Surgery, Nara Medical University, Nara, Japan

Abstract

Postoperative recurrence of c-ros oncogene 1 (ROS1)-rearranged non-small cell lung cancer is rarely reported, and the role of tyrosine kinase inhibitors (TKIs) remains unclear. We retrospectively reviewed four patients with completely resected ROS1-positive lung adenocarcinoma who developed recurrence, three receiving crizotinib. The median disease-free interval was 33.4 months, and the median overall survival from postoperative recurrence and initial surgery was 40.7 and 71.2 months, respectively. Brain metastases were the most common initial recurrence site (75%). Crizotinib showed limited efficacy with a median progression-free survival of 3.5 months. These findings highlight indolent disease behavior but limited TKI benefit, supporting the need for adjuvant trials.

Contributors' Statement

R.M. contributed to conceptualization, data curation, writing–original draft. R.N. and R.S. contributed to data curation. M.H. contributed to conceptualization, data curation, writing–review and editing.




Publikationsverlauf

Eingereicht: 17. September 2025

Angenommen: 08. Dezember 2025

Accepted Manuscript online:
12. Dezember 2025

Artikel online veröffentlicht:
23. Dezember 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany